Ganli Pharmaceutical: The application for marketing authorization for Ganinsulin injection received a positive opinion from the European Medicines Agency (CHMP).

Ganli Pharmaceutical announced that the company and its wholly-owned European subsidiary, Ganli Pharmaceutical Europe LLC, recently received a notification from the European Medicines Agency that their insulin glargine injection has obtained a positive opinion from the EMA Committee for Medicinal Products for Human Use (CHMP). CHMP recommended the approval of insulin glargine injection as a biosimilar of Lantus SoloStar for marketing authorization in the European Union, for the treatment of diabetes in adults, adolescents, and children aged 2 and above.